Latest news
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $39.73, Implies 15% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:30 GMTRoivant Sciences Ltd reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 13:32:11 GMTROIV: Strong cash reserves and major settlement boost, with key product launch on track for September - TradingViewTradingView · Thu, 06 Aug 2026 12:46:30 GMTROIV: Secured $950M from Moderna, advanced pivotal trials, and prepared for a key product launch - TradingViewTradingView · Thu, 06 Aug 2026 12:00:28 GMTSwitzerland's Roivant Q1 loss widens - TradingViewTradingView · Thu, 06 Aug 2026 11:32:20 GMTRoivant Sciences Ltd. 2026: Revenue $1.44M, EPS ($0.26) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 11:31:03 GMTROIV: Net loss narrowed to $189.8 million, liquidity strong at $3.9 billion, $950M Moderna payment received - TradingViewTradingView · Thu, 06 Aug 2026 11:29:48 GMTRoivant reports Q1 loss, $3.9B cash and $290.6M net loss for quarter - TradingViewTradingView · Thu, 06 Aug 2026 11:23:02 GMT